# Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

> **NCT00365105** · PHASE3 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 261 (actual)

## Conditions studied

- Breast Cancer
- Lung Cancer
- Metastatic Cancer
- Pain
- Prostate Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** Calcium
- **DIETARY_SUPPLEMENT:** Vitamin D
- **DRUG:** zoledronic acid
- **DRUG:** Sm-153
- **RADIATION:** Sr-89

## Key facts

- **NCT ID:** NCT00365105
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-11
- **Primary completion:** 2012-01
- **Final completion:** 2017-02-27
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2024-09-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365105, "Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00365105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*